arkinson's disease psychosis (PDP) is a clinical condition that affects patients diagnosed with Parkinson's disease (PD) and has a spectrum of neuropsychiatric symptoms distinct from the hallmark motor symptoms. Although prior studies have reported on the prevalence of PDP in select European nations, variations in study design complicate study-to-study comparisons. In this study, we surveyed 1,667 medical practitioners across France, Germany, Italy, Spain, and the UK (collectively, the EU-5) to estimate the prevalence of PDP or symptoms of psychosis among patients with PD. Analysis of the survey data suggest approximately 29% of the general PD population in the EU-5 exhibit signs of PDP. Among the PD population, country-specific rates of PDP are estimated at 30% in France, 27% in Germany, 34% in Italy, 30% in Spain and 21% in the UK. These rates appear in line with those reported in prior country-specific studies. Results from the subset of 437 neurologists who proceeded to take the full survey suggest the symptoms of PDP are disruptive to patients or their respective caregivers in approximately 53% of cases. These results provide a resource that enables cross-country comparison of PDP rates across these major European nations.
Parkinson's disease (PD) is a chronic, progressive, neurological disorder; diagnosis is based on its hallmark motor symptoms which include resting tremor, bradykinesia, rigidity and postural instability. [1] [2] [3] It is the second most common neurodegenerative disease after Alzheimer's disease, affecting over 1 million individuals across Europe and more than 10 million worldwide. 3, 4 Parkinson's disease psychosis (PDP) is a distinct non-motor clinical condition that commonly manifests in patients following a primary diagnosis of PD. The condition is characterised by a spectrum of symptoms associated with psychosis such as illusions, false sense of presence, hallucinations and delusions. 5 Hallucinations in PD are typically visual, unlike in schizophrenia where hallucinations are often auditory. 6 PDP diagnostic criteria developed by the US-based National Institute of Neurological Disorders and Stroke (NINDS)/National Institute of Mental Health (NIMH) work group include having a prior diagnosis of PD and one or more of the aforementioned psychotic symptoms that persist for one month or longer and are not explained by other causes or diagnoses. 5 Treatment guidelines from European healthcare authorities generally recommend use of clozapine or quetiapine if withdrawal of add-on medications and dose adjustment for PD medications are insufficient to control the symptoms of psychosis; however, there are safety and efficacy concerns with the use of these drugs. [7] [8] [9] Understanding the epidemiology of PDP is important, in part, because the chronic, progressive and debilitating condition can magnify the clinical, humanistic and economic burden of PD on patients, communities and healthcare systems. Risk factors for PDP include new medications and changes to existing PD medications, older age, advanced or late-stage PD, dementia, as well as vision and sleep disorders. 10 Symptoms of PDP vary in severity and can be disruptive to the patient. Studies in patients with PD have associated symptoms of psychosis with increased odds of reporting suicidal or death ideation 11, 12 and increased mortality risk. 13, 14 Multiple studies have also reported positive associations between PDP and dementia, as well as with neuropsychiatric symptoms such as depression and anxiety, suggesting patients with PDP are likely to have high comorbidity burdens. [15] [16] [17] The symptoms of PDP can also be disruptive to caregivers. Family members are often the party to take on caregiver responsibilities for patients with PDP. 18 Multiple studies have found that caregivers of patients with PDP report higher burdens, increased depression and lower quality of life compared with caregivers of PD patients without psychosis. 16, 19, 20 Finally, studies in patients with PD have identified psychosis as one of the most common reasons for hospitalization 21, 22 and hallucinations as the strongest predictor of placement into nursing homes 23, 24 suggesting patients with PDP are likely to incur higher healthcare resource utilisation than patients without psychosis.
Though prevalence data on PDP in European nations already exist, estimates vary widely by country and study. Variations in study design, such as data-gathering methods, study inclusion/exclusion criteria, definitions of PDP and symptoms of psychosis complicate study-to-study comparisons, which can make aggregate epidemiological data from a meta-analysis difficult to interpret. A key prospective longitudinal study in Norway has reported the cumulative prevalence of PDP at 60% among 230 patients with PD followed over the 12-year study, with point prevalence rates ranging from 18-49%. 25 We surveyed medical practitioners in France, Germany, Italy, Spain and the UK (collectively, the EU-5) to gain a clearer picture of PDP epidemiology and treatment patterns across this region. The current study presents estimates on the prevalence and severity of PDP among patients with PD in the EU-5 based on the survey data. Trends identified within this region could potentially predict trends across the broader EU. Measures taken to encourage survey participation included honoraria for respondents who were deemed qualified to take the full survey, and recruitment via email, telephone and fax using large physician databases.
Methods

Survey design
All surveys were translated and administered in the local language. 
Data analysis
The diagnosis of PDP and symptoms of psychosis were based on the assessment of the medical practitioner. An analysis of responses to two of the screener questions (Q10 and Q11) was used to estimate the prevalence of PDP among the broader PD population. These questions were as follows. An analysis of neurologist-provided responses to four questions from the full survey (Q1, Q3, Q5 and Q6) was used to estimate the frequency at which PDP symptoms are disruptive to patients and their respective caregivers, as well as the rates of severe and mild-to-moderate PD motor symptomology, dementia and CVD among these patients. Q1 and Q3 also were complemented with a question asking the neurologist to rank the top five features they considered when assessing the disruptiveness of psychosis symptoms and severity of PD motor symptomology (Q2). Choices for Q2 were as follows: i. The degree to which the patient's psychosis interferes with his/her ability to sleep at night.
ii. The degree to which the patient's psychosis interferes with the caregiver's ability to sleep at night.
iii. The degree to which the patient is bothered by his/her symptoms of psychosis (unrelated to sleep). iv. The degree to which the patient's caregiver is bothered by the patient's symptoms of psychosis (unrelated to sleep).
v. The frequency of symptoms of psychosis.
vi. The type of symptoms of psychosis the patient is experiencing (i.e., illusions versus visual hallucinations versus delusions).
vii. Whether the patient has insight on his/her psychosis.
viii. The degree to which the patient's psychosis interferes with his/her daily activities.
ix. The degree to which the patient's psychosis negatively impacts his/ her quality of life.
x. The degree to which the patient's psychosis interferes with the caregiver's quality of life.
xi. Other (specify). 
Results
Survey metrics
A total of 1,667 medical practitioners across the EU-5 participated in the survey. Of these, 1,518 responded to both screener questions related to PDP prevalence (Q10 and Q11) and were included in the analysis to estimate prevalence. In this subset, 1,197 (79%)
described their primary specialty as neurology and 74 (5%) described their primary specialty as psychiatry. The remaining 247 participants (16%) described their primary specialty as general practice, family practice, internal medicine, geriatrics or 'other'.
Of the participants included in the prevalence analysis, 758 (50%)
primarily practised in the academic/teaching hospital setting, 415 (27%) primarily practised in an office or clinic setting, and 319 (21%) primarily practised at a community hospital. The remaining 26 participants (2%) primarily practised in other settings. Countryspecific breakdowns of survey participants by primary specialty areas are reported in Table 2 .
Only 437 participants (26%) were eligible to take the full patient records survey based on their responses to the screener questions. The number of respondents surveyed by country is reported in Table 3 .
Parkinson's disease psychosis prevalence 
Disruptiveness and comorbidity rates
Based on responses from the 437 neurologists surveyed, an estimated 53% of patients with PDP in the EU-5 cohort exhibit symptoms of psychosis that are disruptive to the patient or their respective caregivers.
In the subset of patients with disruptive PDP, an estimated 48% have severe underlying PD motor symptomology while the other 52% have mild-to-moderate symptomology. Comorbidity rates are estimated at 10% for dementia and 7% for CVD among patients with disruptive PDP (not mutually exclusive) and were comparable between those with severe or mild-to-moderate PD motor symptomology. [26] [27] [28] [29] [30] [31] Clozapine, for example, requires intensive monitoring due to the risk of serious side effects including agranulocytosis and myocarditis. 32 Despite the need, epidemiological data on the prevalence of PDP in Europe are limited, making it difficult for national governments and regulatory authorities to assess the burden of PDP independently from PD, as well as the cost-effectiveness and budget impact of emerging therapies specifically developed to treat PDP. Data on PDP treatment patterns among neurologists in the EU-5 are also limited and are presented in a separate report. 33 In the current study, the estimated prevalence rates for PDP among patients with PD in the EU-5 nations are in line with those reported in previous studies.
In prior studies covering the EU-5 nations, reported rates of hallucinations and delusions among patients with PD ranged from 10-45% in France, [34] [35] [36] 13-29% in Germany, 37, 38 11-32% in Italy, [39] [40] [41] 15-42% in Spain 42, 43 and 13-55% in the UK. 17, [44] [45] [46] These broad reported ranges highlight the difficulty of carrying out cross-study comparisons. Common variations in study design identified from a targeted literature review (unpublished findings) include the criteria for patient selection, the definition of PDP, the symptoms of psychosis that were of interest to study investigators, differences in the methodology used to assess symptoms, and the timeframe over which symptoms were observed. For example, several studies have reported that inclusion of minor phenomena increases the observed prevalence rate of psychosis symptoms among patients with PD [47] [48] [49] and that standard assessment tools for PD symptomology, such as the thought disturbance item on the Unified Parkinson Disease Rating Scale (UPDRS) Part I have low sensitivity for capturing such phenomena. 50, 51 The prevalence rates in the current study were estimated based on survey data reported retrospectively by medical practitioners. Most respondents are likely to have used standard diagnostic criteria, clinical judgment and assessment tools to diagnose PDP and symptoms of psychosis. The need to modify existing diagnostic criteria and assessment tools for PDP to capture minor phenomena is discussed elsewhere in the literature. 5, 47, 50 The 29% estimated prevalence rate for PDP in the EU-5 overall also aligns with the 12-year longitudinal population study in Norway reporting the 18-49% range for point prevalence of PDP, 25 suggesting the current study results could be useful for approximating PDP prevalence in other It is important to note that estimated prevalence rates from the current assessments of what they consider to be disruptive versus non-disruptive psychosis and severe versus mild-to-moderate PD motor symptomology, which includes a degree of subjectivity. Reasonable efforts were made during the survey design, targeting and analysis steps to preserve the integrity of the collected data. The estimated prevalence from the current study align with those reported in prior studies suggesting survey respondents answered questions in good faith and that data integrity was not significantly compromised.
Conclusion
No other study to date has assessed the prevalence of PDP in the EU-5 using a consistent methodology that would enable straightforward comparison of prevalence rates between countries. Results of the current study provide a resource that enables cross-country comparison of PDP rates across these major European nations and could potentially be used in studies to estimate the prevalence of PDP across the broader EU. The results also could facilitate studies to assess the burden of PDP and cost effectiveness of emerging new therapies independently of PD. A report of survey data related to treatment patterns for patients with PDP in the EU-5 is presented in a separate report. 33 
